stBM(260,"tree28f5",[1,"http://www.ms-id.org/barometer2008/menu","http://www.ms-id.org/barometer2008/","blank.gif",0,"left","default","hand",0,0,-1,-1,-1,"none",0,"#CCCCCC","transparent","","repeat",1,"expand_f.gif","expand_uf.gif",9,9,0,"line_def0.gif","line_def1.gif","line_def2.gif","line_def3.gif",1,0,0,3,"center",0,1,0,"","","","",""]); stBS("p0",[0,0,"",-2,"",-2,50,-1,3]); stIT("p0i0",["Navigation Menu","","main","","","","",0,0,"bold 9pt 'Verdana'","#666666","none","transparent","","no-repeat","bold 9pt 'Verdana'","#666666","none","transparent","","repeat-x","bold 9pt 'Verdana'","#666666","none","transparent","","no-repeat","bold 9pt 'Verdana'","#666666","underline","transparent","","no-repeat",1,1,"left","middle",0,0,"","","","",0,0,0]); stIT("p0i1",["The MS Barometer explained","the-ms-barometer-explained/what-is-the-ms-barometer.html",,,,,,,,"9pt 'Arial'","#006699",,,,,"9pt 'Arial'","#006699","underline",,,,"9pt 'Arial'","#006699","underline",,,,"9pt 'Arial'","#006699"],"p0i0"); stBS("p1",[,1],"p0"); stIT("p1i0",["What is the MS Barometer?",,,,,,,,,,,,,,,,,,,,"no-repeat"],"p0i1"); stIT("p1i1",["Why the MS Barometer?","the-ms-barometer-explained/why-the-ms-barometer.html"],"p1i0"); stIT("p1i2",["How does the MS Barometer work?","the-ms-barometer-explained/how-does-the-ms-barometer-work.html"],"p1i0"); stIT("p1i3",["How is the MS Barometer structured?","the-ms-barometer-explained/how-is-the-ms-barometer-structured.html"],"p1i0"); stIT("p1i4",["Who provides data for the MS Barometer?","the-ms-barometer-explained/who-provides-data-for-the-ms-barometer.html"],"p1i0"); stIT("p1i5",["How will the MS Barometer be used?","the-ms-barometer-explained/how-will-the-ms-barometer-be-used.html"],"p1i0"); stES(); stIT("p0i2",["Section1: Access to treatments & therapies",""],"p0i1"); stBS("p2",[],"p0"); stIT("p2i0",["Neurologist PwMS ratio","access-to-treatments/index.html"],"p1i0"); stBS("p3",[],"p0"); stIT("p3i0",["Q1.1: If you divide the estimated number
of PwMS in your country by the number of
practising neurologists in your country,
what is the relation figure?"],"p2i0"); stES(); stIT("p2i1",["MS Training for health professionals","access-to-treatments/index.html#Q1.2"],"p1i0"); stBS("p4",[],"p0"); stIT("p4i0",["Q1.2: Is certified training on MS for health
professionals available in your country?"],"p2i1"); stIT("p4i1",["Q1.3: For whom is MS training available?","access-to-treatments/index.html#Q1.3"],"p1i0"); stIT("p4i2",["Q1.4: For whom is MS training resulting in
qualified certification?","access-to-treatments/index.html#Q1.4"],"p1i0"); stES(); stIT("p2i2",["Immunomodulating therapy ","access-to-treatments/index.html#Q1.5"],"p1i0"); stBS("p5",[],"p0"); stIT("p5i0",["Q1.5: Can PwMS in your country be treated
according to the recommendations outlined
in the EMSP Consensus Paper \'Escalating
Immunomodulatory Therapies in MS\'?"],"p2i2"); stIT("p5i1",["Q1.6: What % of PwMS currently receive DMD
treatment in your country?","access-to-treatments/index.html#Q1.6"],"p1i0"); stIT("p5i2",["Q1.7: Is there a limit to the duration of
treatment with DMDs other than for medical
reasons decided by the neurologist and
PwMS together?","access-to-treatments/index.html#Q1.7"],"p1i0"); stES(); stIT("p2i3",["Symptomatic Treatment","access-to-treatments/index.html#Q1.8"],"p1i0"); stBS("p6",[],"p0"); stIT("p6i0",["Q1.8: Can PwMS be treated in accordance
with the recommendations outlined
in the EMSP consensus paper \'Symptomatic
Treatment in MS\' in your country?"],"p2i3"); stIT("p6i1",["Q1.9: What % of PwMS currently receive
symptomatic treatment in your country?","access-to-treatments/index.html#Q1.9"],"p1i0"); stIT("p6i2",["Q1.10: Is there a limit to the duration of
symptomatic treatment available other
than for medical reasons?","access-to-treatments/index.html#Q1.10"],"p1i0"); stES(); stIT("p2i4",["Rehabilitation","access-to-treatments/index.html#Q1.11"],"p1i0"); stBS("p7",[],"p0"); stIT("p7i0",["Q1.11: Can PwMS in your country undergo
rehabilitation measures according to the
recommendations outlined in the EMSP
Consensus Paper \'Recommendations for
Rehabilitation Services for People with MS
in Europe\'?"],"p2i4"); stIT("p7i1",["Q1.12: Do specialist MS rehabilitation
clinics exist in your country?","access-to-treatments/index.html#Q1.12"],"p1i0"); stIT("p7i2",["Q1.13: If you divide the number of PwMS
by the number of specialist rehabilitation
clinics, what figure do you come to?","access-to-treatments/index.html#Q1.13"],"p1i0"); stIT("p7i3",["Q1.14: What is the greatest distance
between a specialist rehabilitation centre
and a PwMS?","access-to-treatments/index.html#Q1.14"],"p1i0"); stIT("p7i4",["Q1.15: What percentage of PwMS
currently receives rehabilitation services
as out-patients?","access-to-treatments/index.html#Q1.15"],"p1i0"); stIT("p7i5",["Q1.16: If required, how often is it that
a PwMS can receive rehabilitation services
as an out-patient?","access-to-treatments/index.html#Q1.16"],"p1i0"); stIT("p7i6",["Q1.17: What percentage of PwMS currently
receives rehabilitation services as in-patients?","access-to-treatments/index.html#Q1.17"],"p1i0"); stIT("p7i7",["Q1.18: If required, how often is it that
a PwMS can receive rehabilitation
services as an in-patient?","access-to-treatments/index.html#Q1.18"],"p1i0"); stES(); stIT("p2i5",["Palliative Care","access-to-treatments/index.html#Q1.19"],"p1i0"); stBS("p8",[],"p0"); stIT("p8i0",["Q1.19: Is there a Palliative Care programme
available for people with MS in your country?"],"p2i5"); stES(); stIT("p2i6",["MS Barometer scores per country for section 1","access-to-treatments/index.html#overall"],"p1i0"); stBS("p9",[],"p0"); stIT("p9i0",["MS Barometer score per country on Access
to treatments & therapies "],"p2i6"); stES(); stES(); stIT("p0i3",["Section2: MS Research agenda"],"p0i2"); stBS("p10",[],"p0"); stIT("p10i0",["Q2.1: Are there support schemes managed
by your MS society which contribute
financially to MS Research?","ms-research-agenda/index.html"],"p1i0"); stIT("p10i1",["Q2.2: Are these MS research schemes
supported by public funding?","ms-research-agenda/index.html#Q2.2"],"p1i0"); stIT("p10i2",["Q2.3: Are MS societies consulted in influencing
the national research agendas on MS?","ms-research-agenda/index.html#Q2.3"],"p1i0"); stIT("p10i3",["MS Barometer score per country for section 2","ms-research-agenda/index.html#overall"],"p1i0"); stES(); stIT("p0i4",["Section3: Employment of People with MS"],"p0i2"); stBS("p11",[],"p0"); stIT("p11i0",["Q3.1: Is there an information programme
for employers and trade unions on the
subject of MS or disability on offer
in your country?","employment-of-people-with-ms/index.html"],"p1i0"); stIT("p11i1",["Q3.2: Do MS awareness raising programmes
for the workplace exist?","employment-of-people-with-ms/index.html#Q3.2"],"p1i0"); stIT("p11i2",["Q3.3: Are there incentives in place to hire
or retain people with MS in employment?","employment-of-people-with-ms/index.html#Q3.3"],"p1i0"); stIT("p11i3",["Q3.4: Is it legally possible for a person with
MS to remain at work if he/she has MS?","employment-of-people-with-ms/index.html#Q3.4"],"p1i0"); stIT("p11i4",["Q3.5: Is there flexible working practice
legislation in place for PwMS to avail of?","employment-of-people-with-ms/index.html#Q3.5"],"p1i0"); stIT("p11i5",["Q3.6: What percentage of PwMS are obliged
to take early retirement due to MS?","employment-of-people-with-ms/index.html#Q3.6"],"p1i0"); stIT("p11i6",["Q3.7: Does a pension fund exist for
such type of early retirement?","employment-of-people-with-ms/index.html#Q3.7"],"p1i0"); stIT("p11i7",["Q3.8: Does the pension fund provide
adequate income for people with MS?","employment-of-people-with-ms/index.html#Q3.8"],"p1i0"); stIT("p11i8",["MS Barometer score per country for section 3","employment-of-people-with-ms/index.html#overall"],"p1i0"); stES(); stIT("p0i5",["Section4: Empowerment of People with MS"],"p0i2"); stBS("p12",[],"p0"); stIT("p12i0",["Q4.1: Is there a consultation group/body on
MS that advises Government on MS policies?","empowerment-of-people-with-ms/index.html"],"p1i0"); stIT("p12i1",["Q4.2: Is the national MS society a member
of this group/body?","empowerment-of-people-with-ms/index.html#Q4.2"],"p1i0"); stIT("p12i2",["Q4.3: Are PwMS represented in the
consultation group/body?","empowerment-of-people-with-ms/index.html#Q4.3"],"p1i0"); stIT("p12i3",["Q4.4: Is the MS society a member of the
body that decides on the reimbursement
of a new MS Therapy?","empowerment-of-people-with-ms/index.html#Q4.4"],"p1i0"); stIT("p12i4",["Q4.5: Does the national MS society have
consultative status with your
national administration?","empowerment-of-people-with-ms/index.html#Q4.5"],"p1i0"); stIT("p12i5",["Q4.6: Does the national MS society receive
state financing as the national representative
body of PwMS?","empowerment-of-people-with-ms/index.html#Q4.6"],"p1i0"); stIT("p12i6",["Q4.7: Does a self-management course exist
in your country for people with MS to empower
them to co-manage their own health
as far as possible?","empowerment-of-people-with-ms/index.html#Q4.7"],"p1i0"); stIT("p12i7",["Q4.8: Who runs the self-management
course for PwMS?","empowerment-of-people-with-ms/index.html#Q4.8"],"p1i0"); stIT("p12i8",["Q4.9: Can a PwMS interface with
a multi-disciplinary team in the
management of their condition?","empowerment-of-people-with-ms/index.html#Q4.9"],"p1i0"); stIT("p12i9",["MS Barometer score per country for section 4","empowerment-of-people-with-ms/index.html#overall"],"p1i0"); stES(); stIT("p0i6",["Section5: Reimbursement of MS costs"],"p0i2"); stBS("p13",[],"p0"); stIT("p13i0",["Q5.1: Are DMDs for PwMS reimbursed?","reimbursement-of-ms-costs/index.html"],"p1i0"); stIT("p13i1",["Q5.2: What percentage of DMD
costs are reimbursed?","reimbursement-of-ms-costs/index.html#Q5.2"],"p1i0"); stIT("p13i2",["Q5.3: Is symptomatic therapy
for PwMS reimbursed?","reimbursement-of-ms-costs/index.html#Q5.3"],"p1i0"); stIT("p13i3",["Q5.4: What percentage of the costs
for symptomatic therapy is reimbursed?","reimbursement-of-ms-costs/index.html#Q5.4"],"p1i0"); stIT("p13i4",["Q5.5: Are rehabilitation services for
PwMS reimbursed?","reimbursement-of-ms-costs/index.html#Q5.5"],"p1i0"); stIT("p13i5",["Q5.6: What percentage of rehabilitation
costs is reimbursed?","reimbursement-of-ms-costs/index.html#Q5.6"],"p1i0"); stIT("p13i6",["Q5.7: Are accessibility adaptations made
in the home by PwMS reimbursed?","reimbursement-of-ms-costs/index.html#Q5.7"],"p1i0"); stIT("p13i7",["Q5.8: What percentage of home adaptation
costs is reimbursed?","reimbursement-of-ms-costs/index.html#Q5.8"],"p1i0"); stIT("p13i8",["Q5.9: Are employers reimbursed for
accessibility adaptations made in the
workplace to accommodate PwMS?","reimbursement-of-ms-costs/index.html#Q5.9"],"p1i0"); stIT("p13i9",["Q5.10: What percentage of workplace
adaptation costs is reimbursed?","reimbursement-of-ms-costs/index.html#Q5.10"],"p1i0"); stIT("p13i10",["Q5.11: What percentage of your country\'s
GDP is spent on healthcare?","reimbursement-of-ms-costs/index.html#Q5.11"],"p1i0"); stIT("p13i11",["MS Barometer score per country for section 5 ","reimbursement-of-ms-costs/index.html#overall"],"p1i0"); stES(); stIT("p0i7",["Section6: Accurate MS Data collection"],"p0i2"); stBS("p14",[],"p0"); stIT("p14i0",["Q6.1: Does a national MS register exist?","accurate-ms-data-collection/index.html"],"p1i0"); stIT("p14i1",["Q6.2: Is the register supported by
public funding?","accurate-ms-data-collection/index.html#Q6.2"],"p1i0"); stIT("p14i2",["Q6.3: Who manages the MS register?","accurate-ms-data-collection/index.html#Q6.3"],"p1i0"); stIT("p14i3",["Q6.4: If a register exists, what %
of people with MS are currently
recorded on the register?","accurate-ms-data-collection/index.html#Q6.4"],"p1i0"); stIT("p14i4",["Q6.5: Does the information coming from
the MS register have an influence on the
national policy for PwMS?","accurate-ms-data-collection/index.html#Q6.5"],"p0i1"); stIT("p14i5",["MS Barometer score per country for section 6","accurate-ms-data-collection/index.html#overall"],"p0i1"); stES(); stIT("p0i8",["Section7: MS Medication coming to the market"],"p0i2"); stBS("p15",[],"p0"); stIT("p15i0",["Q7.1: How long does it take for your national
drug regulatory to adopt an MS drug approved
by EMEA?","ms-medication-coming-to-the-market/index.html"],"p1i0"); stIT("p15i1",["Q7.2: Is the approval of an MS drug automatically
linked to its reimbursement through the
Health Fund/Insurer?","ms-medication-coming-to-the-market/index.html#Q7.2"],"p1i0"); stIT("p15i2",["Q7.3: How long, on average, does it take to get
a decision on drug reimbursement once it has
been approved by the national drug
regulatory authority?","ms-medication-coming-to-the-market/index.html#Q7.3"],"p1i0"); stIT("p15i3",["MS Barometer score per country for section 7","ms-medication-coming-to-the-market/index.html#overall"],"p1i0"); stES(); stIT("p0i9",["MS Barometer score per country in 2008","ms-barometer%20score-per-country-in-2008/index.html"],"p0i1"); stIT("p0i10",[" MS-ID Website","http://www.ms-id.org/","_blank","Visit MS-ID Website"],"p0i1"); stES(); stEM();